Q1 2023 Holdings
Filed 2023-05-15 | 72 holdings | $2.7B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $465.3M | 21,751,284 | 17.0% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $140.4M | 4,739,004 | 5.1% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $131.4M | 2,131,100 | 4.8% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $107.3M | 4,955,588 | 3.9% |
| Ionis Pharmaceuticals Inc(IONS) | COM | 462222100 | $91.5M | 2,560,761 | 3.3% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $86.8M | 3,775,900 | 3.2% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $83.7M | 2,165,109 | 3.1% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $82.3M | 6,730,983 | 3.0% |
| Repare Therapeutics Inc(RPTX) | COM | 760273102 | $81.6M | 8,291,988 | 3.0% |
| Point Biopharma Global Inc | COM | 730541109 | $76.8M | 10,563,748 | 2.8% |
| Xoma Corp del(XOMA) | COM NEW | 98419J206 | $76.7M | 3,633,743 | 2.8% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $74.1M | 9,275,158 | 2.7% |
| 4D Molecular Therapeutics in(FDMT) | COM | 35104E100 | $68.9M | 4,007,413 | 2.5% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $65.4M | 1,827,958 | 2.4% |
| Merus N V | COM | N5749R100 | $54.8M | 2,978,420 | 2.0% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $53.1M | 5,870,000 | 1.9% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $52.1M | 3,239,595 | 1.9% |
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $51.4M | 3,120,521 | 1.9% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $45.3M | 2,143,197 | 1.7% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $44.0M | 2,736,613 | 1.6% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $41.6M | 1,750,000 | 1.5% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $39.7M | 2,561,000 | 1.5% |
| Lexicon Pharmaceuticals Inc(LXRX) | COM NEW | 528872302 | $39.2M | 16,149,179 | 1.4% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $37.8M | 2,143,036 | 1.4% |
| CTI Biopharma Corp(CTIC1USD) | COM | 12648L601 | $37.0M | 8,813,021 | 1.4% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $36.3M | 9,423,215 | 1.3% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $33.7M | 2,455,089 | 1.2% |
| Cullinan Oncology Inc(CGEM) | COM | 230031106 | $32.7M | 3,196,701 | 1.2% |
| Rain Oncology Inc | COM | 75082Q105 | $30.8M | 3,526,729 | 1.1% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $28.1M | 1,846,154 | 1.0% |
| Aclaris Therapeutics Inc(ACRS) | COM | 00461U105 | $27.2M | 3,360,941 | 1.0% |
| Allakos Inc(ALLKGUSD) | COM | 01671P100 | $27.0M | 6,060,247 | 1.0% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $26.4M | 7,611,503 | 1.0% |
| Essa Pharma Inc(EPIEUR) | COM NEW | 29668H708 | $26.0M | 8,748,629 | 0.9% |
| Iteos Therapeutics Inc(5E7) | COM | 46565G104 | $24.6M | 1,810,835 | 0.9% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $20.5M | 1,521,948 | 0.7% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $19.2M | 1,585,677 | 0.7% |
| Third Harmonic BIO Inc(THRD) | COM | 88427A107 | $18.0M | 4,365,933 | 0.7% |
| Calliditas Therapeutics AB | SPONSERED ADS | 13124Q106 | $18.0M | 750,000 | 0.7% |
| Jasper Therapeutics Inc | COM | 471871103 | $17.9M | 9,900,000 | 0.7% |
| Vigil Neuroscience Inc(VIGL) | COM | 92673K108 | $17.8M | 1,813,633 | 0.6% |
| Ovid Therapeutics Inc(OVID) | COM | 690469101 | $17.7M | 6,851,051 | 0.6% |
| AC Immune SA(ACIU) | SHS | H00263105 | $17.4M | 7,428,379 | 0.6% |
| Sutro Biopharma Inc | COM | 869367102 | $15.5M | 3,347,946 | 0.6% |
| An2 Therapeutics Inc(ANTX) | COM | 037326105 | $15.4M | 1,563,963 | 0.6% |
| Glycomimetics Inc(GLYCEUR) | COM | 38000Q102 | $12.0M | 9,544,262 | 0.4% |
| Ikena Oncology Inc | COM | 45175G108 | $10.9M | 3,169,164 | 0.4% |
| Cytomx Therapeutics Inc(CTMX) | COM | 23284F105 | $10.0M | 6,595,801 | 0.4% |
| Aravive Inc(VSAREUR) | COM | 03890D108 | $9.6M | 4,784,214 | 0.3% |
| Verve Therapeutics Inc | COM | 92539P101 | $9.4M | 650,000 | 0.3% |